Ivosidenib in relapsed or refractory acute myeloid leukemia: a profile of its use in the USA (vol 35, pg 160, 2019)

被引：0
|
作者：
McCafferty, Emma H. [1 ]
Lyseng-Williamson, Katherine Ann [1 ]
机构：
[1] Springer, Private Bag 65901,Mairangi Bay, Auckland 0754, New Zealand
来源：
DRUGS & THERAPY PERSPECTIVES | 2019年 / 35卷 / 09期
关键词：
D O I：
10.1007/s40267-019-00645-5
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The original article has been corrected.
引用
收藏
页码：460 / 460
页数：1
相关论文
共 50 条
  • [31] Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant
    Courtney D. DiNardo
    Eytan M. Stein
    Arnaud Pigneux
    Jessica K. Altman
    Robert Collins
    Harry P. Erba
    Justin M. Watts
    Geoffrey L. Uy
    Thomas Winkler
    Hongfang Wang
    Sung Choe
    Hua Liu
    Bin Wu
    Stephanie M. Kapsalis
    Gail J. Roboz
    Stéphane de Botton
    Leukemia, 2021, 35 : 3278 - 3281
  • [32] Ivosidenib (IVO) prior to hematopoietic cell transplant for patients with IDH1-mutant relapsed or refractory acute myeloid leukemia (R/R AML).
    Dinardo, Courtney Denton
    Stein, Eytan
    Pigneux, Arnaud
    Altman, Jessica K.
    Collins, Robert
    Erba, Harry Paul
    Watts, Justin M.
    Uy, Geoffrey L.
    Kapsalis, Stephanie M.
    Liu, Hua
    Winkler, Thomas
    Roboz, Gail J.
    de Botton, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia (vol 7, pg 1490, 2001)
    Bross, PF
    Beitz, J
    Chen, G
    Duffy, E
    Kieffer, L
    Roy, S
    Sridhara, R
    Rahman, A
    Williams, G
    Pazdor, R
    CLINICAL CANCER RESEARCH, 2002, 8 (01) : 300 - 300
  • [34] Characterization of upregulated adhesion GPCRs in acute myeloid leukemia(vol 212, pg 26, 2019)
    Yang, Jiawen
    Wu, Sharon
    Alachkar, Houda
    TRANSLATIONAL RESEARCH, 2025, 275 : 62 - 62
  • [35] Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Analyses
    Wang, Hongfang
    Choe, Sung
    DiNardo, Courtney D.
    Stein, Eytan M.
    de Botton, Stephane
    Fathi, Amir T.
    Tallman, Martin S.
    Kantarjian, Hagop M.
    Stone, Richard M.
    Quek, Lynn
    Zhang, Vickie
    Liu, Hua
    Attar, Eyal C.
    Wu, Bin
    BLOOD, 2019, 134
  • [36] Vincristine Sulfate Liposome Injection A Guide to Its Use in Refractory or Relapsed Acute Lymphoblastic Leukemia
    Harrison, Tracy S.
    Lyseng-Williamson, Katherine A.
    BIODRUGS, 2013, 27 (01) : 69 - 74
  • [37] Vincristine Sulfate Liposome InjectionA Guide to Its Use in Refractory or Relapsed Acute Lymphoblastic Leukemia
    Tracy S. Harrison
    Katherine A. Lyseng-Williamson
    BioDrugs, 2013, 27 : 69 - 74
  • [38] Impact of an automatic palliative care consultation trigger on healthcare use in patients with relapsed/refractory acute myeloid leukemia
    Xiang, Jenny Jing
    Prsic, Elizabeth Horn
    Adelson, Kerin B.
    Ozyck, Rosemary
    Prebet, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
  • [39] First Salvage Therapy for Relapsed or Refractory Acute Myeloid Leukemia: Associated Health Care Resource Use and Costs
    Muffly, Lori
    Young, Christopher
    Nimke, David
    Sullivan, Loretta
    Feng, Qi
    Pandya, Bhavik J.
    BLOOD, 2021, 138 : 1936 - +
  • [40] Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy
    Galkin, Maria
    Jonas, Brian A.
    CORE EVIDENCE, 2019, 14 : 3 - 17
12345